Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
676 Leser
Artikel bewerten:
(3)

Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights

FELTON, California, Oct. 29, 2019 /PRNewswire/ -- The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025. Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases. Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.

The identification of severity among patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective research and development (R&D) activities in the area of genetics is anticipated to foster industry growth as well.

Get Sample PDF and read more details about the "Epigenetics Market" Report 2025.

Several diagnostic and testing organization have launched innovative products including antibodies specific for identification of modifications and advanced kits for simple and efficient detection of biomarkers. Furthermore, development of therapeutic drugs by healthcare providers is anticipated to work in favor of the epigenetics market. Introduction of pipeline drugs and rising approval rate from local and international authorities is estimated to augment epigenetics industry growth over the coming years.

Rising approval rate for therapeutic drugs and epigenetics services is the key industry trend over the past few years. For example, Eli Lilly and Co., global pharmaceutical company, has unveiled its product line of advanced therapeutic drugs Ramucirumab (Cyramza), which is recently approved by FDA. Shifting focus towards the epigenetics services by pharmaceutical companies for detecting of methylation markers during cancer treatment is expected to favor epigenetics industry growth. Epigenomics AG has developed Epi proLung BL Reflex Assay that allows simple diagnosis for lung cancer.

Epigenetics services allows understanding of phenotype changes, which involves alterations in the DNA sequence. Epigenetics testing is performed on various blood sample taken during different time period in person's life. The fast paced technological advancement in epigenetics testing and sequencing methodologies, has led to the vast expansion of epigenetics testing in preventive healthcare management.

The key players are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc, and Sigma-Aldrich Corp.

Browse 153 page research report with TOC on "Global Epigenetics Market" at: https://www.millioninsights.com/industry-reports/epigenetics-market-size

Market Segment:

  • Epigenetics Product Outlook (Revenue, USD Million, 2014 - 2025)
    • Reagents
    • Kits
      • ChIP sequencing kit
      • Whole Genomic Amplification Kit
      • Bisulfite Conversion kit
      • RNA sequencing kit
      • Others
    • Instruments
    • Enzymes
    • Services
  • Epigenetics Technology Outlook (Revenue, USD Million, 2014 - 2025)
    • DNA Methylation
    • Histone Methylation
    • Histone Acetylation
    • Large noncoding RNA
    • MicroRNA Modification
    • Chromatin structures
  • Epigenetics Application Outlook (Revenue, USD Million, 2014 - 2025)
    • Oncology
      • Solid Tumors
      • Liquid Tumors
    • Non Oncology
      • Inflammatory Diseases
      • Metabolic Diseases
      • Infectious Diseases
      • Cardiovascular Diseases
  • Epigenetics Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East and Africa (MEA)
      • South Africa

Browse latest market research reports available with Million Insights:

  • Biologics Market
  • Biosimilars Market
  • Inhalation Anesthesia Market
  • Thermal Spray Coatings Market

About Million Insights:

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact:

Ryan Manuel
Research Support Specialist, USA
Million Insights
Phone: 1-408-610-2300
Toll Free: 1-866-831-4085
Email: sales@millioninsights.com

Web: https://www.millioninsights.com/

Blog: https://millioninsights.blogspot.com/

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.